Compound ID | 3059
Lolamicin
Class: Lipoprotein transport system inhibitor (LolCDE inhibitor)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae, and Enterobacter cloacae, but not active against Gram-positives; targets the lipoprotein transport system |
| Description: | Synthetic compound; derived by combining pyridinepyrazole and pyridineimidazole and further modified to improve accumulation in Gram-negative; shows no activity against Gram-negative gut commensals; reduces bacterial burden by 3-log when administered orally in mice infected with colistin-resistant Escherichia coli; no activity against |
| Year first mentioned: | 2024 |
| Development status: | Experimental |
| External links: | |
| Guide to Pharmacology: | lolamicin |
| Main Source: | https://www.nature.com/articles/s41586-024-07502-0 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.